19 results about "Methyl xanthine" patented technology

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

The present invention relates to an oral extended-release dosage form of 7-methylxanthine (7-MX) or a pharmaceutically acceptable salt thereof. The dosage form is designed for twice-daily administration and provides controlled release of the active agent, achieving pharmacokinetic characteristics including sustained plasma concentrations and reduced fluctuation compared to immediate-release formulations. The invention further relates to the use of such dosage forms in the treatment of myopia, wherein the extended-release characteristics enhance therapeutic effectiveness in myopia.

The invention discloses a preparation method of 1, 7-dimethylxanthine, which adopts inosine as a starting material, and the developed catalyst porphyrin-loaded xanthine oxidase and nano metal oxide can be recycled for multiple times, thereby greatly lowering the production cost. More importantly, safety accidents occur frequently in recent years, a route design strategy for avoiding dangerous reactions becomes more and more important, and the route avoids the use of a diazotization dangerous process, so that the production safety risk is greatly reduced.

The present disclosure relates to mutant enzymes and bacterial strains constructed to produce paraxanthine and 7-methylxanthine from caffeine and methods for the manufacture and use thereof.

The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises 1-methylxanthine and optionally other compounds that modulate the effects of 1-methylxanthine. Uses for the 1-methylxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and / or decreased appetite.

The present invention discloses compositions comprising methylxanthines in combination with disaccharides derived from enzymatic conversion of sucrose. More particularly, the present invention discloses compositions comprising methylxanthines and disaccharides derived from enzymatic conversion of sucrose selected from turanose, leucrose, trehalulose and isomaltulose or in combinations thereof.

The invention relates to the technical field of crystallization control of chemical bulk drug intermediates, and particularly provides a crystallization method of a pentoxifylline intermediate, which comprises the following steps: adding an acetic acid solution into a 3, 7-dimethylxanthine neutralization reaction solution at 80-85 DEG C until crystals are separated out, carrying out heat preservation and stirring for a first preset time, filtering, washing, and drying to obtain the pentoxifylline intermediate. And continuously adding an acetic acid solution to adjust the pH value of the system to be neutral, carrying out heat preservation stirring for a second preset time, slowly cooling to 45-55 DEG C, carrying out heat preservation stirring for a third preset time, and carrying out solid-liquid separation to obtain the pentoxifylline intermediate. According to the crystallization method provided by the invention, the problems of difficulty in centrifugal separation, easiness in blockage of filter cloth and redness of a wet product caused by high viscosity of a solid-liquid mixture in an existing staged cooling and crystal growing process are solved, the yield of the prepared 3, 7-dimethylxanthine product reaches 65% or above, the purity can reach 99.9% or above, the production efficiency is improved, and the crystallization method is suitable for large-scale industrial production.

The invention discloses an intermediate for synthesizing 7-methylxanthine as well as a synthesis method and application of the intermediate, 4-amino-1-methylimidazole-5-carboxylic acid ethyl ester is taken as a raw material and reacts with cyanate to synthesize 4-ureido-1-methylimidazole-5-carboxylic acid ethyl ester, and finally, sodium hydroxide is used for alkali ring closing to obtain the 7-methylxanthine.

A fermentation process for the preparation of xanthine and xanthine derivatives. The disclosure generally relates to a fermentation process for the preparation of xanthine or xanthine derivatives such as 7-methylxanthine (7-MX), theobromine, theophylline, 3-methylxanthine or mixtures thereof. The process results in improved yield and increased efficiency on industrial scale compared to batch process of preparation.

The present invention relates to cocrystals of Methylxanthines with Stilbenoids as coformers, their polymorphic forms and to the process for preparation thereof. The debittering of Methylxanthines is carried out by co-crystallization using Stilbenoids as coformers. The invention further relates to the preparation of polymorphic forms of debittered cocrystals and their use in nutraceutical and pharmaceutical compositions.

The invention relates to the technical field of biological culture, and particularly discloses a culture medium for improving synthesis of unsaturated fatty acid in cell culture fat, which is used for solving the problem that the content of unsaturated fatty acid in the culture fat is not satisfactory. The differentiation culture medium comprises the following components: a basic culture medium, a specific porcine adipose-derived mesenchymal stem cell differentiation induction factor and an unsaturated fatty acid additive. Wherein the specific induction factors comprise but are not limited to factors such as insulin, dexamethasone, indometacin, 3-isobutyl-1-methylxanthine, rosiglitazone and the like. The unsaturated fatty acid additive comprises alpha-linolenic acid, and by adding the substances into the culture medium, the differentiation efficiency of the porcine adipose-derived mesenchymal stem cells and the directional synthesis of the unsaturated fatty acid in the cells can be improved. According to the improved differential culture medium, cell differentiation and unsaturated fatty acid synthesis are effectively promoted by optimizing components and proportions, and the improved differential culture medium has an important application prospect.

The invention relates to an inducer and an induction method for adipose differentiation of mesenchymal stem cells, and the inducer for adipose differentiation of mesenchymal stem cells is characterized in that 3-isobutyl-1-methylxanthine IBMX, insulin, indometacin, fetal calf serum, dexamethasone sodium phosphate, astragaloside, resveratrol and iridoside A are contained in a DMEM (dulbecco's modified eagle medium) high glucose culture medium. When the mesenchymal stem cells are cultured, only the inducer is used, and different proportions of inducers do not need to be added into a culture medium like the prior art; moreover, the adipose differentiation induction time is shortened, the adipose differentiation induction rate is not lower than 91.3% after culture is carried out for 15 days, and the adipose differentiation induction rate is not lower than 94.8% after culture is carried out for 21 days.

The invention discloses a tumor blood vessel blocking type light diagnosis and treatment reagent and a preparation method thereof.The preparation method comprises the steps that in the nitrogen atmosphere, aza-BODIPY molecules NBDP and a blood vessel blocking reagent 5, 6-dimethylxanthine-4-acetic acid are dissolved in a dichloromethane medium; the light diagnosis and treatment molecule NVDA is obtained through a reaction by taking NVDA as a substrate, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) as a carboxyl activating reagent and 4-dimethylaminopyridine as a reaction catalyst. The optical diagnosis and treatment reagent NVDA nano-particles can selectively destroy tumor blood vessels and realize high-resolution blood vessel NIR-II fluorescence imaging so as to dynamically monitor the damage process of the tumor blood vessels; under the irradiation of 808 nm laser, the NVDA nanoparticles can efficiently generate I-type active oxygen species, and also show the photothermal conversion efficiency as high as 44%; the NIR-II fluorescent imaging-mediated I-type photodynamic therapy, photothermal therapy and vascular disruption combined therapy for deep tumor tissues can be used for efficiently killing tumor cells.

The present disclosure provides engineered microbial cells, compositions, and methods of use thereof for producing methylxanthines including theobromine and caffeine.

The present invention provides a combination of Bifidobacterium longum subsp. infantis, lacto- N-fucopentaose I (LNFP-I) and a HMO mixture for use in therapy by promoting the production of one or more beneficial metabolites selected from uridine, adenine, guanine, AMP, cAMP, 4-guanidinobutyric acid, p-hydroxyphenyllactic acid, acetyl-carnitine and 3-methylxanthine in the gastrointestinal tract of an infant or young child, wherein the HMO mixture consists of 2'- fucosyllactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), and 3'-sialyllactose (3SL), and optionally 3-fucosyllactose (3FL) and / or lacto-N-neotetraose (LNnT).

The present invention relates to cocrystals of Methylxanthines with Stilbenoids as coformers, their polymorphic forms and to the process for preparation thereof. The debittering of Methylxanthines is carried out by co-crystallization using Stilbenoids as coformers. The invention further relates to the preparation of polymorphic forms of debittered cocrystals and their use in nutraceutical and pharmaceutical compositions.

A method and composition for accelerating alcohol metabolism and / or preventing or alleviating a hangover, and a related use thereof in the preparation of foods, beverages, nutritional supplements, and animal feeds for accelerating alcohol metabolism. The composition comprises an effective amount of ergothioneine or a pharmaceutically acceptable salt, acid, ester, analogue or derivative thereof, and can also optionally comprise an effective amount of paraxanthine or 1-methylxanthine.

Provided are methods for treating a disease or condition associated with reduced autophagy in a patient, which includes administering to the patient, either simultaneously or sequentially, a therapeutically effective amount of a synergistic combination of compounds from at least two and preferably three of the classes of compounds selected from a saccharide, a vitamin, a ketone body, a polyphenol, and a methylxanthine. The compounds may be present in a subtherapeutic effective amount relative to the compound's dosing when given as a single agent. Also provided are pharmaceutically acceptable compositions and kits including at least two and preferably three of the named classes of compounds.

The present disclosure provides engineered microbial cells, compositions, and methods of use thereof for producing methylxanthines including theobromine and caffeine.